AEye, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing; the supplied text does not provide a separate Q4 income statement or Q4 results. Unless otherwise noted, financial amounts below are in millions of dollars.
Business context
AEye develops active lidar and sensing technology for automotive ADAS and autonomy, mobility, and industrial applications. Its 4Sight A product was in early sample testing with Continental and Hella; 4Sight M began transitioning to commercial production with contract manufacturers in Q4 2021. The company generally relies on Tier 1 suppliers for automotive commercialization and expects royalties on production units, while selling products directly or through integrators in mobility and industrial markets. The August 2021 business combination was accounted for as a reverse recapitalization.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $3.007 | $1.579 |
| Gross profit (loss) | $(0.630) | $0.771 |
| Operating expenses | $62.605 | $27.253 |
| Operating loss | $(63.235) | $(26.482) |
| Net loss | $(65.011) | $(26.551) |
| Net loss per share, basic and diluted | $(0.60) | $(0.26) |
| Cash used in operating activities | $(55.703) | $(19.689) |
- Revenue rose 90%, comprising $1.004 million of prototype sales and $2.003 million of development contracts. Development contracts remained the majority of revenue.
- Gross margin fell from approximately 49% to approximately negative 21%, as cost of revenue increased to $3.637 million, including higher prototype and contract costs and inventory reserves.
- R&D was $26.543 million, sales and marketing $10.548 million, and general and administrative expense $25.514 million. Operating expenses increased 130% overall.
- At year-end, cash and cash equivalents were $14.183 million and marketable securities were $149.824 million, totaling approximately $164.0 million. Current assets were $177.365 million and current liabilities $13.568 million.
- No borrowings were outstanding at December 31, 2021; convertible notes and bank loans were repaid or converted in connection with the business combination. Total liabilities were $17.386 million.
- Investing cash outflow of $151.546 million primarily reflected purchases of available-for-sale securities, not operating investment alone. Financing provided $207.084 million, including business-combination and PIPE proceeds.
- Management said existing cash, cash equivalents, marketable securities, and expected CSPA proceeds were expected to fund operations and capital needs for at least 12 months from the March 28, 2022 filing date. The company reported accumulated deficit of $151.8 million and expects significant losses through at least 2024.
Material changes versus FY2020
- Revenue increased by $1.428 million, but cost of revenue rose by $2.829 million, turning gross profit into a gross loss.
- Net loss widened by $38.460 million, driven primarily by higher R&D, sales and marketing, and public-company and administrative costs.
- Operating cash use increased by $36.014 million. Year-end liquidity increased substantially following the business combination and PIPE financing; the company also invested proceeds in marketable securities.
- Revenue concentration shifted: the filing says Continental represented approximately 55% of 2021 revenue, while one customer represented 66% in 2020. Automotive applications generated 76% of 2021 revenue versus 79% in 2020.
Outlook, risks, and unusual items
- No formal revenue or earnings guidance is provided. Management expects automotive technology licensing to begin generating revenue in 2024, and anticipates Continental production capacity beginning in 2024. These expectations depend on design wins, OEM purchasing decisions, validation, and production schedules.
- The company expected its transition to contract manufacturers to be complete by mid-2022. Automotive development and qualification may take five to seven years or longer; design wins do not assure production revenue.
- Continental is a key commercial partner and a major revenue customer. Failure to secure OEM awards or progress the relationship could materially impair prospects. The filing also identifies customer concentration, uncertain lidar adoption, pricing pressure, competition, and dependence on limited or single-source components as significant risks.
- COVID-19 and supply-chain disruptions, inflation, semiconductor constraints, and the Russia-Ukraine conflict may affect operations, customers, sourcing, and costs. Management said the size and duration of potential effects were uncertain.
- The $2.297 million PPP loan-forgiveness gain benefited FY2021 results. A $1.583 million expense was recorded for commitment shares issued under the Tumim Stone common stock purchase agreement.
- The Tumim Stone agreement permits, subject to conditions and share limits, up to $125 million of stock purchases over 36 months. No shares had been sold under it at year-end, and a resale registration statement had not yet been filed; management anticipated filing in April 2022. Use could dilute existing holders.
- Management identified a material weakness in internal control over financial reporting, citing insufficient qualified accounting and IT personnel and deficiencies in GAAP application, risk assessment, and control design. Disclosure controls were deemed ineffective at year-end; remediation was in progress. The auditor gave an unqualified opinion on the financial statements but did not attest to control effectiveness.
- The filing reports no material pending legal proceedings and no expected dividends in the foreseeable future.
Key facts for investors to verify
- Whether Continental or other Tier 1 partners secure OEM design wins, and when those programs convert into production and royalty revenue.
- How quickly revenue scales beyond development contracts and prototypes, and whether gross margins improve as manufacturing volumes and costs change.
- Cash burn, liquidity runway, and any financing needs; review the conditional CSPA terms and potential dilution alongside outstanding equity awards and warrants.
- Progress and testing of the internal-control remediation plan, given the disclosed material weakness and ineffective disclosure controls.
- Customer concentration and exposure to supply constraints, product qualification delays, and slower-than-expected lidar adoption.